BIM Mediates EGFR Tyrosine Kinase Inhibitor-Induced Apoptosis in Lung Cancers with Oncogenic EGFR Mutations by Costa, Daniel B et al.
BIM Mediates EGFR Tyrosine Kinase Inhibitor-
Induced Apoptosis in Lung Cancers with
Oncogenic EGFR Mutations
Daniel B. Costa
1, Bala ´zs Halmos
2, Amit Kumar
3, Susan T. Schumer
1, Mark S. Huberman
1, Titus J. Boggon
3,
Daniel G. Tenen
1, Susumu Kobayashi
1*
1 Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America, 2 University Hospitals
of Cleveland and Case Western Reserve University, Cleveland, Ohio, United States of America, 3 Department of Pharmacology, Yale University School of Medicine, New
Haven, Connecticut, United States of America
Funding: See section at end of
manuscript.
Competing Interests: The authors
have declared that no competing
interests exist.
Academic Editor: Ingo K.
Mellinghoff, University of California
Los Angeles, United States of
America
Citation: Costa DB, Halmos B, Kumar
A, Schumer ST, Huberman MS, et al.
(2007) BIM mediates EGFR tyrosine
kinase inhibitor-induced apoptosis
in lung cancers with oncogenic EGFR
mutations. PLoS Med 4(10): e315.
doi:10.1371/journal.pmed.0040315
Received: May 11, 2007
Accepted: September 14, 2007
Published: October 30, 2007
Copyright:  2007 Costa et al. This
is an open-access article distributed
under the terms of the Creative
Commons Attribution License, which
permits unrestricted use,
distribution, and reproduction in any
medium, provided the original
author and source are credited.
Abbreviations: CML, chronic
myelogenous leukemia; EGFR,
epidermal growth factor receptor;
ERK, extracellular signal-regulated
protein kinase; GIST, gastrointestinal
stromal tumors; MAPK, mitogen-
activated protein kinase; NSCLC,
non-small cell lung cancer; PARP,
poly (ADP-ribose) polymerase; SD,
standard deviation; siRNA, small
interfering RNA; TKI, tyrosine kinase
inhibitor; WT, wild type
* To whom correspondence should
be addressed. E-mail: skobayas@
bidmc.harvard.edu
ABSTRACT
Background
Epidermal growth factor receptor (EGFR) mutations are present in the majority of patients
with non-small cell lung cancer (NSCLC) responsive to the EGFR tyrosine kinase inhibitors (TKIs)
gefitinib or erlotinib. These EGFR-dependent tumors eventually become TKI resistant, and the
common secondary T790M mutation accounts for half the tumors with acquired resistance to
gefitinib. However, the key proapoptotic proteins involved in TKI-induced cell death and other
secondary mutations involved in resistance remain unclear. The objective of this study was to
identify the mechanism of EGFR TKI-induced apoptosis and secondary resistant mutations that
affect this process.
Methods and Findings
To study TKI-induced cell death and mechanisms of resistance, we used lung cancer cell lines
(with or without EGFR mutations), Ba/F3 cells stably transfected with EGFR mutation constructs,
and tumor samples from a gefitinib-resistant patient. Here we show that up-regulation of the
BH3-only polypeptide BIM (also known as BCL2-like 11) correlated with gefitinib-induced
apoptosis in gefitinib-sensitive EGFR-mutant lung cancer cells. The T790M mutation blocked
gefitinib-induced up-regulation of BIM and apoptosis. This blockade was overcome by the
irreversible TKI CL-387,785. Knockdown of BIM by small interfering RNA was able to attenuate
apoptosis induced by EGFR TKIs. Furthermore, from a gefitinib-resistant patient carrying the
activating L858R mutation, we identified a novel secondary resistant mutation, L747S in cis to
the activating mutation, which attenuated the up-regulation of BIM and reduced apoptosis.
Conclusions
Our results provide evidence that BIM is involved in TKI-induced apoptosis in sensitive EGFR-
mutant cells and that both attenuation of the up-regulation of BIM and resistance to gefitinib-
induced apoptosis are seen in models that contain the common EGFR T790M and the novel
L747S secondary resistance mutations. These findings also suggest that induction of BIM may
have a role in the treatment of TKI-resistant tumors.
The Editors’ Summary of this article follows the references.
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Sequencing of the epidermal growth factor receptor (EGFR)
gene in a large number of tumor samples has identiﬁed
somatic activating mutations in the tyrosine-kinase pocket of
EGFR [1,2]. These mutations were ﬁrst described in non-small
cell lung cancer (NSCLC) patients treated with speciﬁc EGFR
tyrosine kinase inhibitors (TKIs)—geﬁtinib and erlotinib—
who had radiographic and clinical responses to such agents
[3–5]. Two recent transgenic mouse models, in which the
overexpression of EGFR mutations was targeted in type II
pneumocytes, demonstrated that these mutations led to the
development of adenocarcinomas and that the tumors
responded both to suppression of the EGFR driving signal
and EGFR TKIs [6,7]. As data accumulate, it seems clear that
EGFR-mutant ‘‘oncogene-addicted’’ cancers represent a dis-
tinct form of NSCLC that can be targeted through novel
approaches [8]. The tumor cells are dependent on, or
addicted to, the EGFR mutated oncogene for both main-
tenance of the malignant phenotype and cell survival. At the
time of this writing, phase II trials in which patients with
advanced NSCLC are included on the basis of presence of the
two most common EGFR mutations (either exon 19 deletions
or the exon 21 arginine-for-leucine substitution at amino
acid 858, or L858R) and are given geﬁtinib as ﬁrst-line
treatment show radiographic response rates that exceed 75%
[9–11]. Mature results of such trials will likely conﬁrm the
improved time to progression and survival seen in retro-
spective studies of patients treated with TKIs in which EGFR
mutations had been identiﬁed [12–15].
Despite the unprecedented responses seen in these speciﬁc
EGFR-mutant tumors, most eventually become resistant to
the TKIs and disease progression is noted. Our group and
others have identiﬁed a second mutation in the EGFR kinase
domain (the exon 20 methionine to threonine substitution at
position 790, or T790M) in repeat tissue samples from
patients who initially responded to TKIs but later progressed
[16,17]. The two largest cohorts of patients with TKI-resistant
NSCLCs, in which a second biopsy was obtained after
progression, identiﬁed the T790M mutation in around 50%
of the samples and one D761 secondary mutation [18,19].
Recently, in four out of 18 (22%) TKI-resistant EGFR-mutant
tumors, ampliﬁcation of another oncogene, MET,w a s
identiﬁed [20]. Other secondary mutations and alternative
mechanisms of resistance have not been completely clariﬁed.
One of the major effects of TKIs in sensitive EGFR-mutant
cell lines is their induction of apoptosis. The exquisite
sensitivity of these NSCLCs to geﬁtinib and erlotinib [3–5]
has been supported by the concept of ‘‘oncogene addiction’’
[6,7,21]. A recent report suggested that a common signaling
cascade may be involved during apoptosis in cells that
depend on oncogenic SRC, BCR-ABL, and mutant EGFR
[22]. Interestingly, the BH3-only proapoptotic proteins BIM
(also referred to as BCL2-like 11, or BCL2L11), and to a lesser
extent BAD (BCL2 antagonist of cell death), mediate
imatinib-induced apoptosis of BCR-ABL leukemic cells [23].
The key downstream mediators of TKI-induced cell death in
EGFR-mutant tumors remain unknown. We hypothesized
that the BH3-only members might be involved in the
apoptotic signal following EGFR disruption by TKIs.
In this study we studied BIM’s role in TKI-induced
apoptosis in EGFR-mutant lung cancers. In addition, we
investigated the effect of the resistant mutation T790M and a
novel secondary mutation, L747S, on the regulation of BIM
and apoptosis.
Methods
Patient Characteristics and Clinical Course after TKI
Treatment
Two EGFR mutation-positive patients with geﬁtinib-resist-
ant NSCLCs and secondary EGFR mutations were identiﬁed
from our Thoracic Oncology Clinic database. Their clinical
and molecular characteristics, as well as their response to TKI
treatment, are detailed in Table S1. Both patients are part of
an Institutional Review Board-approved protocol, and
written informed consent was obtained for the analysis of
their tumors.
Reagents
Geﬁtinib and erlotinib were purchased from a commercial
supplier. CL-387,785 was purchased from Calbiochem (Darm-
stadt, Germany). Stock solutions for geﬁtinib, erlotinib, and
CL-387,785 were prepared as previously described [16].
Sequencing of the EGFR Gene
Both genomic DNA and total RNA were extracted from the
tumor cells of a transbronchial biopsy and of pleural ﬂuid in
patients 1 and 2 (Table S1), respectively. Genomic DNA was
used as a template for sequencing exons 18–21 as previously
published [3]. cDNA was transcribed from 1 lg of total RNA
with Superscript II Reverse Transcriptase (Invitrogen, Carls-
bad, CA). The cDNA was used as a template for subsequent
PCR ampliﬁcations of EGFR. The kinase domain of the EGFR
coding region was ampliﬁed by the use of two sets of
oligonucleotides and sequenced: (1) sense primer (59-GCA
CAG GAC GGG GAC CAG ACA ACT-39) and antisense
primer (59-GGA CAT AGT CCA GGA GGC AG-39); (2) sense
primer (59-GCA CAG GAC GGG GAC CAG ACA ACT-39) and
antisense primer (59-ATG GGT GGC TGA GGG AGG CGT
TCT-39). The PCR products containing exons 19–21 ampliﬁed
by the use of the latter set of primers were subcloned into the
pGEM-T Easy cloning vector (Invitrogen) and sequenced [16].
Cell Culture
Ba/F3 cell lines were maintained in RPMI supplemented
with 10% FBS and 5% WEHI conditioned medium as the
source of IL3. The human lung cancer-derived cells lines
A549, NCI-H460 (H460), NCI-H1975 (H1975), NCI-H3255
(H3255), PC-9, and HCC827 were maintained in RPMI
supplemented with 10% FBS.
EGFR Mutant Constructs and Transfections
The L747S mutation was introduced into human EGFR
wild-type (WT) or L858R constructs in the context of the
pcDNA3.1 expression vector (Invitrogen) [16] using the
QuikChange XL Site-Directed Mutagenesis Kit (Stratagene,
La Jolla, CA). The oligonucleotides sequences were as follows:
sense primer, 59-CGT CGC TAT CAA GGA ATC AAG AGA
AGC AAC ATC TC-39; antisense primer, 59-GAG ATG TTG
CTT CTC TTG ATT CCT TGA TAG CGA CG-39. The
resulting constructs were conﬁrmed by sequencing. For
transient transfection experiments, COS-7 cells were plated
at a concentration of 5 3 10
4 cells per well in six-well plates.
The following day, these cells were transfected with 1 lgo f
PLoS Medicine | www.plosmedicine.org October 2007 | Volume 4 | Issue 10 | e315 1670
BIM in EGFR TKI-Induced Apoptosisthe expression constructs using Fugene 6 (Roche) and
incubated for 12 h when the medium was changed to
serum-free. After 12 h of serum starvation, cells were
stimulated with 100 ng/ml EGF (Sigma). TKIs were added to
the culture medium 3 h prior to the addition of EGF. Cells
were exposed to EGF for 15 min. Stable Ba/F3 cell and
HCC827 cell lines carrying WT or other mutant EGFR were
generated and maintained as previously described [24,25].
Western Blotting and Antibodies
Whole-cell lysates were prepared as previously described
[16,26]. The human lung cancer cells lines were treated in
RPMI supplemented with 10% FBS in the presence of EGFR
inhibitors as indicated. Ba/F3 cells were washed three times
with RPMI only and stimulated by EGF as previously
described [24]. Geﬁtinib, erlotinib, or CL-387,785 at increas-
ing concentrations were added to the medium as indicated in
the ﬁgure legends.
EGFR, caspase-3, BCL-xL, Bcl2 (mouse speciﬁc), and total
STAT5 antibodies were purchased from Santa Cruz Bio-
technology (Santa Cruz, CA). Total extracellular signal-
regulated protein kinase (ERK) antibody was purchased from
BD Transduction Laboratories (Lexington, KY). Phospho-
EGFR (pTyr1068), phospho-STAT5 (pTyr694), phospho-AKT
(pS473), phospho-ERK1/2 (pT202/pY204), BCL2 (human
speciﬁc), BIM, BAD, phospho-BAD (pS112), poly (ADP-ribose)
polymerase (PARP), cleaved-PARP, and AKT antibodies were
purchased from Cell Signaling Technology (Beverly, MA).
BIM antibody was also purchased from Stressgen (Victoria,
Canada). Actin antibody was purchased from Sigma (St.
Louis, MO).
Cell Proliferation Assay
Cell counts were performed at daily intervals using Trypan
blue dye exclusion. Growth inhibition was assessed by
CellTiter 96 AQueous One solution proliferation kit (Prom-
ega, Madison, WI) [24]. Brieﬂy, Ba/F3 stable cells were washed
three times with RPMI 1640 only and resuspended in RPMI
1640 supplemented with 10% FBS and 20 ng/ml EGF (Sigma,
St. Louis, MO). Then, cells were transferred to triplicate wells
at 10,000 cells/well in 96-well ﬂat-bottom plates with various
concentrations of inhibitors and the cells were incubated for
48 h.
Flow Cytometric Analysis of Cell-surface Exposure of
Phosphatidylserine and Mitochondrial Membrane
Potential
For ﬂow cytometric analysis, cells were plated at 1 3 10
5/
well in six-well plates and treated with DMSO or EGFR
inhibitors. Cell-surface exposure of phosphatidylserine was
assessed using an Annexin-V-FLUOS staining kit (Roche,
Basel, Switzerland) as previously described [24]. For assess-
ment of mitochondrial membrane potential, Ba/F3 cells were
incubated with 40 nM DiOC6(3) (Molecular Probes, Eugene,
OR) in PBS for 15 min at room temperature as previously
described [27].
RNA Interference
BIM-speciﬁc and negative control small interfering RNAs
(siRNAs) were purchased from Cell Signaling Technology and
Dharmacon Research (Lafayette, CO), respectively. Cells were
transfected with TransIT-TKO transfection reagent (Mirus,
Madison, WI) according to the manufacturer’s protocol in the
presence of siRNAs. After 24 h of transfection, cells were
washed with RPMI twice and incubated with RPMI containing
10% FBS in the presence of DMSO (control), geﬁtinib, or
CL387,785 for 48 h.
Statistical Analysis
The paired Student t-test was used to determine statistical
signiﬁcance. A p-value less than 0.01 was considered
signiﬁcant.
Results
Apoptosis in NSCLCs with and without EGFR Mutations
We selected a set of NSCLC cell lines to identify the
differential sensitivity of wild-type (WT) EGFR and mutant
tumors to the apoptotic effects of geﬁtinib. A549 and H460
have WT EGFR and are highly resistant to geﬁtinib (reported
geﬁtinib sensitivity for proliferation [IC50] are 9.6 and 12.9
lM, respectively) [28], whereas H1650 and HCC827 have a
deletion in exon 19 (delE746-A750) with different geﬁtinib
sensitivities (IC50: 1 and 0.005 lM, respectively) [28]. H3255
carries the L858R EGFR exon 21 point mutation and has an
IC50 of 0.015 lM to geﬁtinib [28]. In addition, we also tested
PC-9 cells, which have the delE746-A750 EGFR mutation and
are sensitive to reversible EGFR tyrosine kinase inhibitors [22].
After 48 hours of 1 lM geﬁtinib treatment, all the EGFR
mutant cell lines showed an increase in the percentage of
apoptotic cells when compared to untreated cells (Figure 1).
However, the HCC827, H3255, and PC-9 cells had a greater
increase in the amount of apoptotic cells after treatment than
did the H1650 cells. The non-EGFR mutant A549 and H460
cells displayed almost no changes in the number of apoptotic
cells after geﬁtinib treatment (Figure 1).
Up-Regulation of BIM in EGFR-Mutant NSCLCs Sensitive to
Gefitinib
Knowledge of the differential degrees of apoptotic in-
duction by geﬁtinib in these cell lines prompted us to test our
hypothesis that the BH3-only BIM is involved in the cell death
execution process mediated by TKIs. The BIM gene encodes
three major isoforms: BIM short (BIMs), BIM long (BIML), and
BIM extra long (BIMEL). All isoforms contain a BH3 domain
that can bind to and inactivate members of the antiapoptotic
BCL2 family of proteins [29].
As shown in Figure 2, geﬁtinib treatment induced rapid
and sustained increase in the levels of BIMEL and BIML in
HCC827, H3255 and PC-9. Two major pathways regulate BIM
expression and/or function: the PI3K-AKT-FOXO and the
ERK1/2 mitogen-activated protein kinase (MAPK) pathways
[29,30]. Consistent with these reports, we detected that the
relative electrophoretic migration BIMEL and BIML was faster
when HCC827, H3255, and PC-9 cells were treated with
geﬁtinib, which suggests that BIMEL and BIML were hypo-
phosphorylated due to loss of AKT and/or ERK activity
(Figure 2), or other EGFR downstream targets. In contrast,
there was no sign of hypophosphorylation or marked up-
regulation of BIM in A549 and H460 cells, possibly because of
sustained phosphorylation of AKT/ERK (Figure 2). In H1650
cells, there was a slight increase in the level of BIMEL (Figure
2), consistent with the degree of apoptosis seen in these cells
(Figure 1). Changes in the proapoptotic BAD and the
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with cell death upon geﬁtinib exposure (Figure 2).
These ﬁndings suggest that BIM may be a key marker or
effector of geﬁtinib-induced apoptosis in EGFR-mutant lung
cells.
The T790M Secondary Resistant Mutation Abrogates the
Up-Regulation of BIM by Reversible TKIs
If an increase in BIM expression is important for geﬁtinib-
induced apoptosis, it should be suppressed upon treatment of
cell lines expressing the resistant T790M EGFR mutation
[16,17] with geﬁtinib. We tested this hypothesis in geﬁtinib-
sensitive HCC827 stable cell lines expressing activating
deletion mutant L747-S752 (HCC/Del) EGFR or in the
geﬁtinib-resistant lines HCC827-delL747-S752-T790M (HCC/
Del-TM), harboring both the delL747-S752 and T790M
mutations [25], as well as the H1975 cell line harboring
L858R-T790M double mutations [24,25].
Geﬁtinib induced rapid inactivation of EGFR, AKT, and
ERK, and a dramatic increase of BIM in both HCC827 with an
empty vector (HCC827/Emp) and HCC/Del cells (Figure 3A).
In contrast, the HCC/Del-T790M and H1975 cells had
minimal up-regulation of BIM, and the EGFR signaling
cascade was less inhibited by geﬁtinib (Figure 3). Previously,
we showed that the irreversible EGFR inhibitor, CL-387,785,
can overcome geﬁtinib resistance and lead to apoptosis in
HCC/Del-T790M [25] and H1975 cells [24]. After exposure to
CL-387,785 a decrease in phosphorylations of EGFR, AKT,
and ERK were observed and accompanied by marked up-
regulation of BIM, which correlated with the presence of the
cleaved form of PARP (Figure 3).
These results conﬁrm that up-regulation of BIM correlates
with effective TKI-induced apoptosis and that T790M
suppresses this process in geﬁtinib-treated cells.
Knockdown of BIM Attenuates TKI-Induced Apoptosis
If BIM functions as a mediator of TKI-induced apoptosis,
knockdown of its expression should have detectable effects
Figure 1. Up-Regulation of BIM Correlates with Gefitinib-Induced Apoptosis in NSCLC Cell Lines
Effect of gefitinib on NSCLC cells. A549, H460, H1650, HCC827, H3255, or PC-9 cells were grown in the presence of 0.1% DMSO (control) or 1 lM
gefitinib for 48 h. Apoptosis was assessed using propidium iodide and Annexin-V staining.
(A) Representative flow cytometry data. The numbers represent percentage of cells in the appropriate quadrant. Left lower quadrant, viable cells; right
lower quadrant, early apoptotic cells; right upper quadrant, late apoptotic cells.
(B) Quantification of apoptosis. The y-axis plots the sum of early and late apoptotic cells as mean 6 standard error of the mean (n   3).
doi:10.1371/journal.pmed.0040315.g001
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in HCC827 and H1975 cells treated with geﬁtinib and
CL387,785, respectively. Apoptosis was signiﬁcantly attenu-
ated by BIM siRNA in both cell lines detected by PARP
cleavage (Figure 4A) and the Annexin V assay (Figure 4B)
after exposure to TKIs that induce dephosphorylation of
EGFR, AKT, and ERK (Figure 4A).
These data suggest that BIM plays an important role as a
death regulator in TKI-induced apoptosis.
Identification and Characterization of a Novel Secondary
Mutation, L747S, in a Gefitinib-Resistant Tumor
Through the sequencing of geﬁtinib-resistant tumors at
our institution we identiﬁed a novel second mutation (see
Methods). We detected a L858R EGFR mutation in the initial
biopsies obtained from a 74-year-old white woman affected
by an advanced adenocarcinoma with bronchioalveolar and
papillary features [31,32]. She maintained a partial response
to geﬁtinib for 40 months without overt clinical or radio-
graphic progression; however, at that point computer
tomography scans showed progression of lung lesions,
presence of a thickened left pleura with effusion (Figure
S1), and bone metastases. Sequencing of the cDNA derived
from the pleural ﬂuid of the progressing tumor conﬁrmed the
persistence of the initial L858R mutation in addition to a new
T–C basepair change in exon 19 (Figure 5A), which results in
a predicted amino acid change of leucine (L) to serine (S) at
position 747 of EGFR. Most subclones contained the L747S in
cis with L858R (Table S1). In the EGFR kinase domain crystal
structures [33,34], L747 is located at the start of the loop
between strand b3 and helix aC. This residue is the leucine of
the LRE motif that is frequently deleted in exon 19. In crystal
structures of both the active and inactive conformations of
the EGFR tyrosine kinase domain this residue is oriented
toward the back pocket region of the catalytic cleft (Figure
5B). Mutations in the analogous residue of ABL1 (L273M) and
ErbB2 (L755S or P) (Figure 5C) have been described in
patients with imatinib-resistant chronic myelogenous leuke-
mia (CML) and solid tumors including gastric, breast, and
lung cancers, respectively [35–37]. However, functional
studies were not performed.
Transient transfection experiments utilizing COS-7 cells
demonstrated that auto-phosphorylation of the original
L858R EGFR was inhibited by lower concentrations of
geﬁtinib or erlotinib than the L858R-L747S or L858R-
T790M constructs (Figure S2A). CL-387,785 partially over-
came the observed inhibition (Figure S2B).
To prove the functional signiﬁcance of the L747S
mutation, we generated Ba/F3 cell lines stably expressing
mutant EGFR constructs [24]. These cell lines, including
L858R-L747S, proliferated in the absence of IL3. However,
the proliferation rate of Ba/F3-L858R-L747S cells was not as
dramatic as that of Ba/F3-L858R-T790M cells (Figure S3). Ba/
F3-L858R cells were extremely sensitive to geﬁtinib (Figure
5D), whereas Ba/F3-L858R-T790M cells were highly resistant
up to 1 lM geﬁtinib. All four Ba/F3-L858R-L747S clones
demonstrated an intermediate pattern of resistance to the
growth inhibition signal induced by geﬁtinib (Figure 5D).
After the cells were exposed to geﬁtinib for 24 h, Ba/F3-L858R
cells were unable to proliferate while Ba/F3-L858R-L747S and
Ba/F3-L858R-T790M cells continued to grow even in the
presence of 1 lM geﬁtinib (Figure 5E).
These results suggest that execution of apoptosis may be
impaired by the presence of T790M and, to a lesser extent,
L747S.
Resistance Mutations Attenuate BIM Up-Regulation and
the Mitochondrial Apoptosis Pathway
Based on the data obtained from lung cancer cell lines, we
further explored the mechanisms by which T790M and L747S
Figure 2. Gefitinib Induces Expression and Dephosphorylation of BIM in Gefitinib-Sensitive EGFR-Mutant Cells, but Not in Cells with Wild-Type EGFR
Cells were treated with 1 lM gefitinib for the times (in hours) indicated, and lysates were collected and proteins analyzed by immunoblotting. The three
isoforms of BIM, BIMEL, BIML, and BIMS are shown. Hypophosphorylated BIM migrates faster than the other species [23].
doi:10.1371/journal.pmed.0040315.g002
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Geﬁtinib effectively induced apoptosis in Ba/F3-L858R cells,
whereas Ba/F3-L858R-L747S cells were intermediately resist-
ant and Ba/F3-L858R-T790M completely resistant (Figure 6A,
top). The up-regulation of BIM was also attenuated in a
similar dose–response manner as seen in the apoptosis assay
(Figure 6A, bottom), with L858R-T790M completely abrogat-
ing the induction of BIM and L858R-L747S attenuating both
the up-regulation of BIM and apoptosis.
Phosphorylated EGFR as well as AKT were maintained up
to 36 h after geﬁtinib treatment in Ba/F3-L858R-L747S and
L858R-T790M cells. The phosphorylated forms of ERK1/2
were signiﬁcantly less inhibited in L858R-T790M cells (Figure
6B). Up-regulation of BIM was observed in Ba/F3-L858R cells
as early as 3 h after exposure to geﬁtinib (Figure 6B). Ba/F3-
L858R-L747S cells had a delay in the up-regulation of BIM
and Ba/F3-L858R-T790M cells had no change in BIM isoforms
(Figure 6B). BAD, BCL-xL, and BCL2 did not change
signiﬁcantly.
In order to explore the consequences of a delay or
inhibition in BIM up-regulation on apoptosis, we examined
whether geﬁtinib induced breakdown of the inner mitochon-
drial membrane potential (DWm), characterized by a sudden
increase in permeability of the mitochondrial membrane as a
consequence of the charge difference between the mitochon-
drial matrix and the cytosol [27,38,39].
Treatment with geﬁtinib led to a signiﬁcant decrease in
DWm in Ba/F3-L858R cells at 12 h (Figure 6C). The pan-
caspase inhibitor z-VAD-fmk did not inhibit the breakdown
of DWm (unpublished data), suggesting that the intrinsic
mitochondrial pathway plays a central role during geﬁtinib-
induced apoptosis. It is well known that the BH3-only
members are part of the intrinsic apoptotic pathway
[40,41]. Ba/F3-L858R-T790M cells showed no signiﬁcant
change even at 24 h (Figure 6C), and Ba/F3-L858R-L747S
cells had no apparent changes at 12 h and only a partial
breakdown at 24 h. Activation of caspase-3 and PARP
cleavage were consistent with the apoptotic execution
process measured by DWm (Figure 6D).
Taken together, these results suggest that the novel L747S
and the T790M mutations attenuate the intrinsic mitochon-
drial apoptosis pathway by inhibiting the up-regulation of
BIM in EGFR-mutant models.
Discussion
We identiﬁed BIM as a key apoptotic effector of EGFR TKIs
in sensitive cells with the activating L858R or exon 19
deletion EGFR mutations. The common T790M secondary
mutation and the novel L747S, in conjunction with an
activating mutation, attenuated the up-regulation of BIM
and apoptosis.
The discovery that the deregulated tyrosine kinase activity
in certain cancers can be targeted has led to major advances
in the ﬁeld of malignant therapeutics [42]. Tyrosine kinases
require ATP for their enzymatic activity, and thus small
molecules that mimic ATP can bind to mutant or trans-
located kinases and inactivate them. The most satisfying
translational example of this process has been in the case of
CML, in which the t(9;22) translocation and the consequent
enhanced tyrosine kinase activity of BCR-ABL can be
effectively inhibited by imatinib. This oral TKI has revolu-
tionized the treatment of CML and led to sustained responses
in a majority of patients [43]. A parallel situation is seen with
gastrointestinal stromal tumor (GIST), in which activating
mutations of the receptor tyrosine kinases c-KIT or PDGFRA
Figure 3. Inhibition of BIM Up-Regulation by the Resistant T790M Mutation
The increase in BIM expression and apoptosis are inhibited by the secondary resistant mutation, T790M.
(A) Modulation of signaling following gefitinib treatment in HCC827 cells expressing EGFR mutants. Time course of gefitinib treatment in HCC827 cells
expressing pcDNA3.1 empty vector (HCC/Emp), EGFR-DelL747-S752 (HCC/Del), or EGFR-DelL747-S752þT790M (HCC/Del-TM). Cells were treated with 3
lM gefitinib or CL-387,785 for indicated times, lysates collected, and proteins analyzed by immunoblotting.
(B) Modulation of signaling following either gefitinib or CL387,785 treatment in H1975 cells. The cells were treated with 1 lM gefitinib or CL-387,785 for
the indicated times and extracts were analyzed by Western blotting.
doi:10.1371/journal.pmed.0040315.g003
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contribute to the disease, and again imatinib is an effective
treatment option improving patient survival [44]. A similar
clinical beneﬁt is observed in patients with lung cancers
harboring the two most common EGFR activating mutations,
L858R and exon 19 deletions [3–5,9].
The striking initial response to small molecule tyrosine
kinase inhibitors is thought to stem from the phenomenon of
‘‘oncogene addiction’’ [21], and a common signaling cascade
may be involved in the apoptosis induced by multiple TKIs
[22]. Rapid inactivation of phosphorylated ERK, AKT, and
STAT3/5, and the delayed accumulation of phosphorylated
p38 are commonly observed in SRC-, BCR-ABL-, and EGFR-
dependent cells after exposure to the speciﬁc inhibitors
SU6655, imatinib, and geﬁtinib, respectively [22].
Recently, it has been shown that BIM is one of the main
effectors of imatinib-mediated apoptosis in BCR-ABL-pos-
itive leukemia cells [23,45,46]. BIM belongs to the BH3-only
group of proteins that bind and neutralize various anti-
apoptotic BCL2 family members so that they cannot inhibit
the proapoptotic effects of BAX and BAK in the intermem-
brane mitochondrial space [40,41]. BIM is regulated by
multiple stimuli, including the PI3K-AKT-FOXO and the
ERK1/2 MAPK pathways [29,30]. Cytokine withdrawal or
inhibition of PI3K-AKT leads to dephosphorylation and
nuclear entry of the forkhead transcription factor FOXO-3A,
which induces BIM mRNA expression [29]. Inhibition of
ERK1/2 also induces BIM mRNA expression by unknown
mechanisms [29]. In addition, ERK1/2 regulates the function
of BIMEL by post-translational modiﬁcations. ERK1/2-de-
pendent phosphorylation antagonizes BIMEL by proteasomal
degradation or disruption of BIMEL-BAX interactions [29].
Of relevance to our studies is that the ErbB family
receptors activate the PI3K-AKT and the ERK1/2-MAPK
pathways, both of which mediate regulation of BIM. Over-
expression of EGFR inhibits anoikis—apoptosis induced by
lack of correct cell and extracellular matrix attachment [47]—
in mammary epithelial cells by restoring ERK activation and
blocking BIM up-regulation, which is reversed by either EGF
withdrawal or EGFR inhibition [48]. It has also been shown
that EGFR affects the post-translational control of BIM
expression through a pathway requiring PKCd and MEK/
MAPK activation [49]. Although the role of p38 as an
apoptosis mediator has not been completely characterized
[22], p38 activity is required for EGFR down-regulation
resulting in attenuation of downstream signaling [50]. In
addition, p38 activation leads to BIM induction during
glucocorticoid-induced apoptosis in lymphoblastic leukemia
cells [51].
These observations and the concept of ‘‘oncogenic shock,’’
which postulates that prosurvival signals are shut down
quickly, whereas proapoptotic signals remain active enough
to induce apoptosis upon oncoprotein inactivation [22],
prompted us to hypothesize that BIM plays an important role
in apoptosis induced by geﬁtinib and other EGFR TKIs. Our
data indicate that the intrinsic mitochondrial pathway is
involved in geﬁtinib-induced cell death and that the up-
regulation of the proapoptotic polypeptide BIM was con-
sistently seen during TKI-induced apoptosis. In addition,
sustained activation of EGFR, AKT, and/or ERK caused by the
T790M and L747S resistant mutations delayed BIM up-
regulation and apoptosis. We also showed, in two distinct
cell lines, that knockdown of BIM led to signiﬁcant reduction
in the amount of cell death. These observations suggest that
Figure 4. Knockdown of BIM Expression Leads to Attenuation of Apoptosis
(A) HCC827 cells (left) or H1975 cells (right) were transfected with BIM siRNA oligonucleotides or control oligonucleotides for 24 h prior to 0.5 lM
gefitinib or 1 lM CL387,785 treatment, respectively. The cells were then treated for 24 and 48 h and lysates were collected and proteins were analyzed
by immunoblotting.
(B) Annexin V apoptosis assay. The cells were treated as above and analyzed after 48 h. The percentage of surviving cells—both Annexin V
  and
propidium iodide
  cells—was compared with 0.1% DMSO control. The data are reported as mean 6 standard deviation (SD) (n   3).
doi:10.1371/journal.pmed.0040315.g004
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driven tumors and that the up-regulation of BIM may be one
of the common mechanisms by which tumor cells driven by
‘‘oncogenic addiction’’ undergo apoptosis and ‘‘oncogenic
shock’’ [22]. However, knockdown of BIM did not completely
inhibit the TKI-induced apoptosis in our cell lines, which may
be explained either by the residual level of BIM protein in
siRNA transfected cells (Figure 4A), or involvement of other
proapoptotic regulators, such as other BH3-only members.
One of the possible candidates is BAD, another BH3-only
proapoptotic regulator, which was shown previously to play a
role in imatinib-induced apoptosis in CML [23]. However, the
role of BAD remains unclear so far, since inhibition of BAD
phosphorylation, which is believed to be important for
preventing apoptosis, was not detected in the NSCLC cells
we tested (Figure 3B and unpublished data). In addition,
double knockdown of BIM and BAD did not show signiﬁcant
increase in the survival of geﬁtinib-treated HCC827 cells
compared to single BIM knockdown (unpublished data).
Further studies are required to deﬁne other relevant
apoptotic pathways involved in geﬁtinib-induced apoptosis.
Furthermore, our data indicate that the degree of BIM up-
regulation was directly proportional to the amount of
apoptosis and that the up-regulation of BIM determines the
sensitivity of lung cancer cells to the apoptotic effects of the
TKIs. This effect became evident when we examined three
cell lines carrying the same EGFR mutation, HCC827, PC-9,
and H1650 (all have the delE746-A750 mutation), and noted
that the degrees of geﬁtinib-induced apoptosis were strik-
ingly different, with the former two being more sensitive than
the later. The up-regulation of BIM was minimal in H1650
cells, which lack PTEN [52], compared to HCC827 and PC-9.
Acquired resistance to imatinib commonly occurs in CML
and often in GIST [53,54]. In both diseases, secondary
Figure 5. Identification of a Novel Secondary Resistant EGFR Mutation, L747S
(A) Sequencing chromatograms with the EGFR L747S exon 19 and L858R exon 21 by RT-PCR.
(B) Amino acid alignments of the tyrosine kinase domain in EGFR, ErbB2, and ABL1.
(C) Active conformation crystal structure of the kinase domain of EGFR in complex with erlotinib [34]. The graphic shows the spatial locations of residues
L747 and L858 as red spheres. The activation loop is orange, helix aC yellow, the glycine-rich P-loop green, and the inhibitor erlotinib yellow. The figure
was made using the program PYMOL (http://pymol.sourceforge.net/). (D) Top: Dose-dependent growth inhibition of Ba/F3 cells expressing EGFR L858R
(LR), L858R-T790M (LR-TM), or L858R-L747S (LR-LS) detected by the MTS assay. Error bars indicate standard deviation (n¼4). Four LR-LS clones (#1–4)
were obtained from G418 selection. Bottom: Expression of EGFR in Ba/F3 cells expressing L858R, L858R-L747S #1–4, or L858R-T790M.
(E) Gefitinib release assay. Ba/F3 cells expressing L858R (LR), L858R-L747S #4 (LR-LS), or L858R-T790M (LR-TM) were plated in 24-well plates at a density
of 1310
5/well and treated with 0.1% DMSO (control) or gefitinib for 24 h. Then the cells were washed three times with RPMI and cultured in medium
containing 20 ng/ml EGF. The cells were stained with Trypan blue and counted daily. The data are reported as mean 6 SD (n ¼ 3).
doi:10.1371/journal.pmed.0040315.g005
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BIM in EGFR TKI-Induced Apoptosismutations in either ABL1 or KIT and PDGFRA have been
identiﬁed as main mechanistic factors that re-establish the
oncogene signaling in these tumors. In the case of CML, more
than 35 mutations have been described in the ABL kinase
domain from patients with imatinib resistance [55], and in
GIST a similar pattern of multiple sites of secondary kinase
domain mutations has been seen [54]. There are many
similarities among structures of tyrosine kinases, and some
of the secondary mutations fall at exactly the same amino
acid residue. This is the case of the T315I, T670I, and T790M
mutations in ABL1, KIT,a n dEGFR,r e s p e c t i v e l y[ 5 6 ] .
Mutation of these key gatekeeper residues can prevent
inhibitor access to the kinase back pocket region and can
disrupt hydrogen bonds or other interactions between the
inhibitor and the kinase [16,56]. Despite the similarity
between CML, GIST, and EGFR-mutated NSCLC in the
patterns of secondary resistance, in NSCLC only the T790M
[16,17] and D761Y [19] secondary mutations have been
described so far.
In this report, we identify and characterize a novel EGFR
secondary mutation, L747S. Our in vitro studies demonstra-
ted that both of the secondary mutations initially identiﬁed
in our lab (T790M and L747S) confer varying degrees of
resistance to the apoptotic signals initiated by geﬁtinib. These
changes may reﬂect the progressing radiological and clinical
pictures of our patients while on geﬁtinib monotherapy for
their metastatic NSCLC. T790M results in ineffective TKI
inhibition and sustained down-stream signaling from the
mutant EGFR [16,17], as was seen in all cell lines carrying
T790M in the current report. EGFR, AKT, and ERK1/2 were
not inhibited in our T790M geﬁtinib-treated models. The
L747 residue is oriented toward the back pocket region of the
Figure 6. The Secondary Resistant Mutations L747S and T790M Affect Gefitinib-Induced Apoptosis and Inhibit BIM Up-Regulation
(A) Top: Annexin V apoptosis assay: Ba/F3 cells expressing L858R (LR), L858R-L747S #4 (LR-LS), or L858R-T790M (LR-TM) cells were grown in the absence
or presence of gefitinib for 24 h. The data are reported as mean 6 SD (n   3). Bottom: After the cells were treated for 3 h with increasing concentrations
of gefitinib, lysates were collected and proteins analyzed by immunoblotting. BIM expression correlated with the amount of apoptosis in L858R, L858R-
L747S, and L858R-T790M cells.
(B) Modulation of signaling following gefitinib treatment in Ba/F3 cells expressing EGFR mutants. Time course of gefitinib treatment in L858R (LR),
L858R-L747S #4 (LR-LS), or L858R-T790M (LR-TM) cells. Cells were treated with 0.2 lM gefitinib for indicated times in the absence of IL3 and in the
presence of EGF 20 ng/ml. Note that increase in BIM expression is delayed in LR-LS cells or minimal in LR-TM cells.
(C) Flow cytometric analysis of the inner mitochondrial membrane potential (DWm) breakdown. Cells were treated in the presence or absence of 0.2 lM
gefitinib for 12 or 24 h, and stained with DiOC6(3).
(D) Activation of caspase-3 and cleavage of PARP are attenuated in L858R-L747S #4 (LR-LS) and L858R-T790M (LR-TM) cells. Cell extracts described in (B)
were analyzed by Western blotting.
doi:10.1371/journal.pmed.0040315.g006
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BIM in EGFR TKI-Induced Apoptosiscatalytic cleft both in the active and inactive conformation of
the EGFR tyrosine kinase domain [33,34]. It is unclear from
the current crystallographic data and from our molecular
dynamics simulations how acquisition of this mutation results
in resistance to ATP-competitive EGFR inhibitors; there may
be differential effects on ATP and small molecule binding, as
seen for L858R and G719S mutations [57] or a shift in the
conformational equilibrium of the kinase between the active
and inactive states. Further crystallographic studies are
required to more fully understand the structural basis for
the effects of this mutation.
Our data show that L858R-L747S demonstrated a pattern
of resistance that was less pronounced than that observed
with L858R-T790M with increasing doses of geﬁtinib (Figures
5D and 6A). These results are similar to the ones observed in
the previously reported secondary L858R-D761Y mutation
[19]. It is possible to conceive that an increase in the clinical
doses of geﬁtinib or switching to erlotinib, which is given at
its maximal tolerated dose [58], may lead to beneﬁcial clinical
effects, possibly by increasing BIM expression, in patients
with EGFR mutations who acquired L747S after exposure to
geﬁtinib.
The data presented here indicate that BIM is both a marker
and an effector of TKI-induced apoptosis in EGFR-mutant
NSCLC cells. Furthermore, we identiﬁed a novel acquired
EGFR secondary mutation, L747S, and showed that both the
L747S and the common T790M in cis to an activating EGFR
mutation (either L858R or an exon 19 deletion) cause
resistance to EGFR TKI-induced apoptosis and attenuate
the up-regulation of BIM. In this context, it is possible that
enhancement of BIM expression or activation of its down-
stream targets may be a promising strategy for the treatment
of EGFR-mutant NSCLC, particularly in the context of
mutations conferring secondary resistance to TKI inhibitors.
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BIM in EGFR TKI-Induced ApoptosisEditors’ Summary
Background. Most cases of lung cancer—the leading cause of cancer
deaths worldwide—are ‘‘non-small cell lung cancer’’ (NSCLC). Many
patients with NSCLC die within a year of their diagnosis, but recently,
‘‘targeted’’ therapies have increased the life expectancy of some of
them. Like all cancers, NSCLC occurs when cells begin to divide
uncontrollably because of changes (mutations) in their genes. Targeted
therapies specifically attack these changes and, unlike standard chemo-
therapy drugs, kill cancer cells without damaging normal cells. The
targeted drugs used to treat NSCLC are gefitinib and erlotinib, two
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs).
In normal cells, messenger proteins bind to EGFR and activate its tyrosine
kinase, an enzyme that sticks phosphate groups on tyrosine (an amino
acid) in other proteins. These ‘‘phosphorylated’’ proteins then tell the
cell to divide. In some NSCLCs, EGFR drives uncontrolled cell division
because its tyrosine kinase is mutated and the cancer becomes
dependent on or ‘‘addicted’’ to EGFR signaling for its survival. TKI
treatment can dramatically shrink this subset of NSCLCs, most of which
lack a specific part of EGFR (the gene that encodes EGFR) or have the
amino acid leucine instead of arginine at position 858 (an L858R
mutation) of EGFR.
Why Was This Study Done? TKI-sensitive NSCLCs eventually become
resistant to TKIs because they acquire additional (secondary) mutations.
In half of these TKI-resistant tumors, the additional mutation is
replacement of threonine by methionine at position 790 (T790M) in
EGFR. However, the mutations responsible for the remaining cases of TKI
resistance are not known. In addition, little is known about how TKIs
induce cell death other than that they induce a type of cell death called
apoptosis. A better understanding of how TKIs kill tumor cells and how
secondary mutations block their effects could reveal ways to enhance
their action and improve the outcome for patients with NSCLC. In this
study, the researchers have studied the mechanism of TKI-induced cell
death and of resistance to TKIs.
What Did the Researchers Do and Find? The researchers first measured
the ability of gefitinib to cause apoptosis (genetically programmed cell
death) in NSCLC cell lines (tumor cells adapted to grow indefinitely in
dishes) that had the EGFR deletion, the L858R mutation, or normal EGFR.
Gefitinib caused apoptosis only in cell lines with altered EGFR. Then they
asked whether a proapoptotic protein called BIM (a member of the BCL2
family of pro- and antiapoptotic proteins) is involved in TKI-induced cell
death—BIM is known to be involved in this process in leukemia (blood
cancer) cells. Gefitinib treatment increased the expression of BIM in TKI-
sensitive NSCLC cell lines and reduced the phosphorylation of BIM
(which makes BIM more active). By contrast, blocking BIM expression
using a technique called RNA interference reduced TKI-induced
apoptosis in TKI-sensitive NSCLC cells. Furthermore, introduction of the
T790M resistance mutation into these cells blocked gefitinib-induced up-
regulation of BIM and apoptosis. Finally, the researchers identified a new
TKI resistance mutation (L747S, substitution of serine for leucine at
position 747) in a patient whose TKI-sensitive NSCLC had become
resistant to gefitinib, and showed that this resistance mutation also
reduced TKI-induced apoptosis in cells growing in dishes by interfering
with BIM up-regulation.
What Do These Findings Mean? These findings (and those reported by
Gong et al. and Cragg et al.) show that BIM is required for TKI-induced
apoptosis in EGFR mutant NSCLC cells. They also show that mutations
that make TKI-sensitive cells resistant to these drugs reduce TKI-induced
apoptosis by preventing the upregulation of BIM. These results were
obtained by examining the behavior of established cell lines growing in
dishes and need to be confirmed in cells freshly isolated from tumors
and in tumors themselves. However, they suggest that the efficacy of
TKIs could be increased by finding ways to increase BIM expression or to
activate other proteins involved in apoptosis Such approaches might be
particularly beneficial for patients with NSCLC whose initially TKI-
sensitive tumors have acquired mutations that make them resistant to
TKIs.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0040315.
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